Health Letters Company

We are redefining the future of healthcare in the peptide and GLP-1 market by offering cutting-edge biologic solutions that combine world-class quality with fair pricing. Our pride lies in producing biosimilars to stringent FDA cGMP standards, enabling patients and healthcare systems to access effective treatments starting at just $100 – a smart and competitive alternative to brands costing upwards of $1,500. Our track record is built on tangible successes; we recently completed the supply of 15 million doses to the Mexican market, generating over $100 million in revenue, demonstrating our robust operational capabilities. Looking ahead, we are confidently targeting a significant revenue increase to $500 million by 2025, with an ambitious expansion plan aiming to surpass $2.5 billion by 2027.